

COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America

From the COViMS Registry

Scott D. Newsome, DO, Anne H. Cross, MD, Robert J. Fox, MD, June Halper, MSN, APN-C, Pamela Kanellis, PhD, Bruce Bebo, PhD, David Li, MD, Gary R. Cutter, PhD, Kottil W. Rammohan, MD, and Amber Salter, PhD

Correspondence

Dr. Newsome
snewsom2@jhmi.edu

Neurol Neuroimmunol Neuroinflamm 2021;8:e1057. doi:10.1212/NXI.0000000000001057

Abstract

Background and Objective

To describe the impact of coronavirus disease 2019 (COVID-19) on people with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

Methods

The COVID-19 Infections in Multiple Sclerosis (MS) and Related Diseases (COViMS) Registry collected data on North American patients with MS and related diseases with laboratory-positive or highly suspected SARS-CoV-2 infection. Deidentified data were entered into a web-based registry by health care providers. Data were analyzed using *t*-tests, Pearson χ^2 tests, or Fisher exact tests for categorical variables. Univariate logistic regression models examined effects of risk factors and COVID-19 clinical severity.

Results

As of June 7, 2021, 77 patients with NMOSD and 20 patients with MOGAD were reported in the COViMS Registry. Most patients with NMOSD were laboratory positive for SARS-CoV-2 and taking rituximab at the time of COVID-19 diagnosis. Most patients with NMOSD were not hospitalized (64.9% [95% CI: 53.2%–75.5%]), whereas 15.6% (95% CI: 8.3%–25.6%) were hospitalized only, 9.1% (95% CI: 3.7%–17.8%) were admitted to the ICU and/or ventilated, and 10.4% (95% CI: 4.6%–19.5%) died. In patients with NMOSD, having a comorbidity was the sole factor identified for poorer COVID-19 outcome (OR = 6.0, 95% CI: 1.79–19.98). Most patients with MOGAD were laboratory positive for SARS-CoV-2, and almost half were taking rituximab. Among patients with MOGAD, 75.0% were not hospitalized, and no deaths were recorded; no factors were different between those not hospitalized and those hospitalized, admitted to the ICU, or ventilated.

Discussion

Among the reported patients with NMOSD, a high mortality rate was observed, and the presence of comorbid conditions was associated with worse COVID-19 outcome. There were no deaths reported in the patients with MOGAD, although these observations are limited due to small sample size.

MORE ONLINE

COVID-19 Resources

For the latest articles, invited commentaries, and blogs from physicians around the world

NPub.org/COVID19

From the Johns Hopkins University School of Medicine (S.D.N.), Baltimore, MD; Washington University in St. Louis School of Medicine (A.H.C., A.S.), MO; Mellen Center for MS (R.J.F.), Cleveland Clinic, OH; Consortium of MS Centers (J.H.), Hackensack, NJ; MS Society of Canada (P.K.), Toronto, Ontario, Canada; National Multiple Sclerosis Society (B.B.), New York, NY; University of British Columbia (D.L.), Vancouver, British Columbia, Canada; The University of Alabama at Birmingham (G.R.C.); and University of Miami School of Medicine (K.W.R.), FL.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

COViMS Registry contributors are listed at links.lww.com/NXI/A539.

The Article Processing Charge was funded by the National MS Society.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

COVID-19 = coronavirus disease 2019; **COViMS** = COVID-19 Infections in MS and Related Diseases; **DMT** = disease-modifying therapy; **ICU** = intensive care unit; **MOGAD** = myelin oligodendrocyte glycoprotein antibody disease; **MS** = multiple sclerosis; **NMOSD** = neuromyelitis optica spectrum disorders; **SARS-CoV-2** = severe acute respiratory syndrome coronavirus 2.

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised concerns about the risks of COVID-19 in those with neuroimmunologic disorders that affect the CNS. Risk factors associated with worse COVID-19 outcomes in multiple sclerosis (MS) include increased hospitalizations with B cell-depleting therapies, recent treatment with glucocorticoid use, and Black or African American race.^{1,2} However, little data have been reported on how COVID-19 affects people with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

NMOSD and MOGAD are distinct disorders that have a spectrum of presentations and unique autoantibodies that differentiate them from MS and other diseases. Disability levels vary in NMOSD and MOGAD, with the former often associated with a greater disability. However, outcomes of COVID-19 in people with NMOSD or MOGAD are largely unknown, especially in those with preexisting medical comorbidities and/or taking specific disease-modifying therapies (DMTs).

The rarity of coexisting SARS-CoV-2 and these autoantibody-associated disorders make them well suited to a registry-based study. The COVID-19 Infections in MS and Related Diseases (COViMS) Registry was designed to collect information on COVID-19 in people with MS, NMOSD, and MOGAD from North American health care professionals. Here, we aimed to describe the clinical characteristics, risk factors for severe course of COVID-19, and overall COVID-19 outcomes in patients with NMOSD and MOGAD.

Methods

Study Design

The COViMS Registry collected data on patients in North America who had a laboratory positive or highly suspected infection with SARS-CoV-2 with MS and other related diseases, including NMOSD and MOGAD.¹ Highly suspected patients for SARS-CoV-2 infection were identified by a health care professional based on typical COVID-19 symptoms and signs (e.g., anosmia, ageusia, shortness of breath, and pneumonia) with no better explanation for their symptoms/signs. Health care professionals were asked to report patients after a minimum of 7 days from initial infectious symptom onset and when sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death.¹ The COViMS Registry is jointly supported by the Consortium

of MS Centers, the National MS Society USA, and the MS Society of Canada.¹

Data collection was de-identified, cross-sectional, and entered into a secure, online database on the COViMS Registry website (COViMS.org) using the REDCap system (project-redcap.org).¹ The Registry was determined to be not human subject research by the WUSTL Institutional Review Board. Data use agreements govern the use of some data that were contributed, and thus, access to individual level data is not permitted by outside researchers.¹ Data collection began April 1, 2020, and is ongoing.¹ The study herein used data collected from April 1, 2020, through June 7, 2021.

COVID-19 Clinical Outcome

Health care professionals indicated whether the patient was hospitalized, admitted to the intensive care unit (ICU), required ventilator support, and/or died during their COVID-19 clinical course, with response options of “yes,” “no,” or “unknown” to each.¹ Unknown responses were considered as not having the outcome.¹ These separate outcomes were used to characterize COVID-19 severity, with the following levels: not hospitalized, hospitalization alone, ICU admission and/or ventilation and death where if more than 1 event was indicated, the patient was assigned to the highest level of event that occurred.¹

Demographic and Clinical Characteristics

Demographic factors collected were sex (male, female, and nonbinary), age, race (White; Black or African American [Black]; Asian; American Indian, Alaska Native, or Indigenous Canadian; Native Hawaiian or Other Pacific Islander; other; or unknown), and ethnicity (Hispanic/Latino, not Hispanic/Latino, other, or unknown).¹

Clinical characteristics collected include disease type (if NMOSD, NMO-IgG or aquaporin-4 antibody status noted), disease duration, and ambulation milestones (fully ambulatory, walks with assistance, and nonambulatory).¹ Comorbid conditions were indicated by selecting all applicable including cancer, cardiovascular disease, cerebrovascular disease, chronic kidney disease, chronic liver disease, chronic lung disease, chronic neurologic and/or neuromuscular disease, diabetes, hypertension, immunodeficiency disease, and morbid obesity.¹ Comorbid conditions were also summed to categorize the count as 0 (reference), 1, 2, and ≥ 3 comorbidities.¹ Cigarette use history was captured as never, past, current, or unknown.¹ Glucocorticoid treatment during the prior 2 months was ascertained.¹ Current DMT at the time of SARS-CoV-2

infection was reported by the provider as one of the following: alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fumarate, diroximel fumarate, eculizumab, fingolimod, glatiramer acetate, hematopoietic stem cell transplant, interferon-beta, intravenous immunoglobulin, methotrexate, mitoxantrone, mycophenolate, natalizumab, ocrelizumab, ofatumumab, ozanimod, rituximab, satralizumab, tocilizumab, siponimod, teriflunomide, other, none, and unknown.¹

Statistical Analysis

The analyses were limited to patients with NMOSD and MOGAD who were laboratory positive or highly suspected for SARS-CoV-2 infection and reported by a health care professional in North America. Cohort characteristics were summarized using mean (SD) for continuous variables, median (interquartile range) for ordinal variables, and frequencies (%) for categorical variables.¹ Comparisons between groups were made using χ^2 tests, Fisher exact tests, and Student *t*-tests, as appropriate, and reported descriptive statistics and *p* values.¹ Similar statistical comparisons were performed between patients with NMOSD and MS who died. Univariate logistic regression models were constructed to examine the effects of risk factors and COVID-19 clinical severity outcome dichotomized as those who were not hospitalized vs those hospitalized alone, admitted to the ICU and/or ventilated or death.¹ The strength of associations was reported using OR and 95% CI. Statistical analyses were conducted using SAS V9.4 (SAS Institute Inc., Cary, NC).¹

Results

Demographic and Clinical Characteristics of Patients With NMOSD

As of June 7, 2021, there were 77 patients with NMOSD reported in the COViMS Registry. Most patients were female (81.6%) and in the United States at the time of COVID-19 (97.2%), with a mean age (SD) of 48.1 (14.1) years (Table 1). Race and ethnicity of patients were diverse with 38.2% Black, 25.0% non-Hispanic White, 17.1% Hispanic or Latino, and 19.7% other racial groups. The average NMOSD disease duration was 9.1 (7) years, and 67.2% were aquaporin-4 IgG seropositive. Although the majority of patients with NMOSD were fully ambulatory (75.7%), some required assistance with ambulation (14.9%), and 9.4% were nonambulatory. At the time of COVID-19 diagnosis, most patients with NMOSD were on rituximab (62.2%), and 9.5% were not on a DMT. Sixty percent had a comorbidity, with hypertension (20.8%), diabetes (15.6%), and morbid obesity (14.3%) being the most frequent comorbidities reported. Only 4 (5.6%) patients with NMOSD were current cigarette smokers.

Almost all (89.6%) patients with NMOSD were laboratory positive for SARS-CoV-2. Fever (57.1%) and dry cough (40.3%) were commonly reported symptoms of COVID-19, whereas 2.6% of patients with NMOSD reported being asymptomatic. Seven patients reported having neurologic symptoms from COVID-19, with motor dysfunction occurring in 3 of the 7 and cognitive and sensory dysfunction each in 2 of

the 7 patients. COVID-19 symptoms lasted 0–6 days in 13.3% of patients with NMOSD, 7–13 days for 22.2%, 14–20 days for 20.0%, and 21 days or longer in 44.4% of patients. Of the 77 patients with NMOSD, 15.6% had pneumonia.

COVID-19 Outcomes in Patients With NMOSD

Most patients with NMOSD were not hospitalized (64.9% [95% CI: 53.2%–75.5%]), whereas 15.6% (95% CI: 8.3%–25.6%) were hospitalized only, and 9.1% (95% CI: 3.7%–17.8%) were admitted to the ICU and/or ventilated. Over 10% (10.4%; 95% CI: 4.6%–19.5%) died. No demographic characteristics were statistically significantly different between those not hospitalized and those hospitalized, admitted to the ICU, ventilated, or died of COVID-19. Having a medical comorbidity was the only statistically significant difference observed; those with a comorbidity were 6-fold more likely to have a poor clinical COVID-19 outcome compared with those with no comorbidity (OR = 6.0, 95% CI: 1.79–19.98).

A description of the demographic and clinical characteristics of those 8 patients with NMOSD who died of COVID-19 is reported in Table 2. All deceased patients with NMOSD had at least 1 medical comorbidity. Five of the 8 (62.5%) fatal NMOSD cases were aquaporin-4 IgG positive, and 4 (50%) were Black or African American. Six (75.0%) of the 8 patients with NMOSD who died of COVID-19 were on rituximab, but the proportion of deaths among those taking rituximab was not statistically different than the proportion among those not on rituximab (6/46 = 13.0% compared with 2/31 = 6.5%, *p* = 0.46). No significant differences were found among those taking rituximab vs those not on rituximab among patients with NMOSD who were hospitalized or worse (6/18 = 33.3% taking rituximab compared with 2/9 = 29.0% not taking rituximab, *p* = 0.68).

Demographic and Clinical Characteristics of Patients With MOGAD

Twenty patients with MOGAD with COVID-19 were reported in the COViMS Registry. Most patients were female (70.0%) with a mean (SD) age of 40.6 (18.7) years. One half identified as non-Hispanic White. The average disease duration was 5.4 (5.0) years, and most patients with MOGAD were fully ambulatory (84.2%). Almost half of the patients with MOGAD were on rituximab at the time of their COVID-19 diagnosis. Forty-seven percent had a comorbidity, with hypertension (25.0%), diabetes (15.0%), and morbid obesity (15.0%) being the most common. Most patients were laboratory positive (95.0%) for SARS-CoV-2. The most common symptoms from COVID-19 reported in these patients with MOGAD were fever (60.0%), fatigue (55.0%), dry cough (45.0%), and shortness of breath (4.0%). The symptom duration was 0–14 days in 25.0% of patients with MOGAD, 14–20 days in 35.0%, 21 days or longer in 10.0%, and unknown in 30.0%. Pneumonia was reported in 4 (20.0%) patients.

COVID-19 Outcomes in Patients With MOGAD

Of the patients with MOGAD, 75.0% (95% CI: 50.9%–91.3%) were not hospitalized, 10.0% (95% CI: 1.2%–31.7%) were

Table 1 COVIMS NMOSD Overall and by Clinical Outcome

Factor	Total (N = 77)	Not hospitalized (n = 50)	Hospitalized, ICU admission/ventilation/death (n = 27)	p Value
Female	62 (81.6)	43 (86.0)	19 (73.1)	0.17 ^b
Age	48.1 (14.1)	46.9 (14.1)	50.3 (14.2)	0.33 ^e
Race				0.13 ^b
Non-Hispanic White	19 (25.0)	11 (22.4)	8 (29.6)	
Black or African American	29 (38.2)	18 (36.7)	11 (40.7)	
Hispanic or Latino	13 (17.1)	12 (24.5)	1 (3.7)	
Other/unknown	15 (19.7)	8 (16.3)	7 (25.9)	
Disease duration^c	9.1 (7.0)	8.6 (6.5)	10.2 (7.9)	0.37 ^a
NMOSD type				0.47 ^b
NMO-IgG/aquaporin-4 antibody (+)	43 (55.8)	28 (56.0)	15 (55.6)	
NMO-IgG/aquaporin-4 antibody (-)	15 (19.5)	8 (16.0)	7 (25.9)	
Unknown	19 (24.7)	14 (28.0)	5 (18.5)	
Ambulatory status				0.21 ^d
Fully ambulatory	56 (75.7)	40 (81.6)	16 (64.0)	
Walk with assistance	11 (14.9)	6 (12.2)	5 (20.0)	
Nonambulatory	7 (9.5)	3 (6.1)	4 (16.0)	
Glucocorticoid during the last 2 months?				0.67 ^d
No	56 (72.7)	36 (72.0)	20 (74.1)	
Yes	6 (7.8)	5 (10.0)	1 (3.7)	
Unknown	15 (19.5)	9 (18.0)	6 (22.2)	
DMT at the time of COVID-19^c				0.63 ^d
Azathioprine	5 (6.8)	4 (8.5)	1 (3.7)	
Eculizumab	5 (6.8)	4 (8.5)	1 (3.7)	
Mycophenolate	5 (6.8)	4 (8.5)	1 (3.7)	
Ocrelizumab	1 (1.4)	0 (0.0)	1 (3.7)	
Rituximab	46 (62.2)	28 (59.6)	18 (66.7)	
Other	5 (6.8)	2 (4.3)	3 (11.1)	
None	7 (9.5)	5 (10.6)	2 (7.4)	
Length of time on current DMT^c				0.49 ^b
<6 months				0.32 ^b
6 or more months	9 (13.8)	7 (17.1)	2 (8.3)	
Have comorbidities?	56 (86.2)	34 (82.9)	22 (91.7)	
No				0.004 ^b
Yes	29 (38.7)	25 (52.1)	4 (14.8)	
Cancer	5 (6.5)	2 (4.0)	3 (11.1)	0.34 ^d
Cardiovascular disease	6 (7.8)	4 (8.0)	2 (7.4)	0.99 ^d
Cerebrovascular disease	1 (1.3)	1 (2.0)	0 (0.0)	0.99 ^d

Continued

Table 1 COViMS NMOSD Overall and by Clinical Outcome (*continued*)

Factor	Total (N = 77)	Not hospitalized (n = 50)	Hospitalized, ICU admission/ventilation/death (n = 27)	p Value
Chronic kidney disease	2 (2.6)	0 (0.0)	2 (7.4)	0.12 ^d
Chronic liver disease	0 (0.0)	0 (0.0)	0 (0.0)	
Chronic lung disease	7 (9.1)	3 (6.0)	4 (14.8)	0.23 ^d
Chronic neurologic disease	4 (5.2)	1 (2.0)	3 (11.1)	0.12 ^d
Diabetes	12 (15.6)	7 (14.0)	5 (18.5)	0.60 ^b
Hypertension	16 (20.8)	9 (18.0)	7 (25.9)	0.41 ^b
Immunodeficiency disease	2 (2.6)	1 (2.0)	1 (3.7)	0.99 ^d
Morbid obesity	11 (14.3)	4 (8.0)	7 (25.9)	0.032 ^b
Other	12 (15.6)	8 (16.0)	4 (14.8)	0.89 ^b
Comorbid conditions count				0.027 ^b
0	32 (41.6)	27 (54.0)	5 (18.5)	
1	24 (31.2)	12 (24.0)	12 (44.4)	
2	10 (13.0)	5 (10.0)	5 (18.5)	
≥3	11 (14.3)	6 (12.0)	5 (18.5)	
Type of COVID-19 diagnosis				0.028 ^b
Laboratory positive	69 (89.6)	42 (84.0)	27 (100.0)	
Suspected COVID-19, not confirmed	8 (10.4)	8 (16.0)	0 (0.0)	

Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy; ICU = intensive care unit; NMOSD = neuromyelitis optica spectrum disorders. Values presented as mean ± SD, median (P25, P75) or N (column %).

^a Pearson χ^2 test.

^b ANOVA.

^c Data not available for all patients. Missing values: sex = 1, age = 1, disease duration = 5, DMT at the time of COVID-19 = 2, and length of time on current DMT = 10.

^d Fisher exact test.

^e Kruskal-Wallis test.

hospitalized, and 15.0% (95% CI: 3.2%–37.9%) were admitted to the ICU and/or ventilated. No deaths were recorded as of June 7, 2021. A full listing of individual MOGAD patient clinical characteristics, COVID-19 clinical outcome, and COVID-19 treatments is provided in Table 3. No demographic characteristic or clinical COVID-19 outcome was statistically different between those not hospitalized and those hospitalized, admitted to the ICU, or ventilated (data not shown and available on request). Notably, these comparisons were limited due to the small number of patients with MOGAD who were reported.

Differences in COVID-19 Deaths Among Patients With NMOSD and MS

Seventy-four patients with MS and 8 patients with NMOSD died during the study time period. There were a few differences in demographic and clinical characteristics between these groups worth noting (Table 4). Specifically, the NMOSD cohort who died were younger (50 ± 19.2 vs 62.1 ± 12.3 , $p = 0.016$), had shorter disease duration (9.3 ± 7.4 vs 20.6 ± 12.1 , $p = 0.012$), and

a greater percentage of patients were on rituximab compared with the patients with MS who died (75% vs 5.4%, $p < 0.001$).

Discussion

The COViMS Registry has provided a platform for collecting clinician-reported data on patients with MS and related disorders who developed COVID-19. These Registry data provide clinicians with useful information about how SARS-CoV-2 infection affects patients with NMOSD and MOGAD and indicate those who might be at greatest risk for more severe COVID-19 outcomes. NMOSD and MOGAD are uncommon, and this study represents the largest cohort of patients with NMOSD and MOGAD with COVID-19 reported to date. A French study of 15 total patients with NMOSD and MOGAD (5 seropositive NMOSD, 5 seronegative NMOSD, and 5 with MOGAD) with COVID-19 reported an association of older age and more disability with hospitalization, but no deaths.³

Table 2 Demographic and Clinical Characteristics of Deceased Patients With NMOSD

Sex	Age	Race	US state at the time of COVID-19 onset	Disease duration (y)	NMOSD antibody serostatus	Ambulatory status	DMT at the time of COVID-19	Comorbidities	Pneumonia	Length of hospital stay	COVID-19 treatments
Female	73	Non-Hispanic White	Colorado	2	Positive	Walk with assistance	None	Cancer, cardiovascular disease, and chronic lung disease	Yes	4–6 d	Hydroxychloroquine, azithromycin, and oxygen therapy
Female	30	Black or African American	Florida	2	Negative	Fully ambulatory	Rituximab	Diabetes and morbid obesity	Yes–bilateral	19–21 d	Antiviral and other antibiotic, convalescent plasma, tocilizumab, and oxygen therapy
Female	55	Other/unknown	Unknown	9	Positive	Walk with assistance	Rituximab	Hypertension	Unknown	30+ d	Unknown
Female	39	Black or African American	Washington	10	Positive	Nonambulatory	Other	Chronic kidney disease and morbid obesity	Unknown	4–6 d	Unknown
Female	26	Black or African American	California	5	Positive	Fully ambulatory	Rituximab	Diabetes and morbid obesity	Yes	Unknown	Unknown
Male	80	Non-Hispanic White	Missouri	25	Negative	Nonambulatory	Rituximab	Hypertension	No	7–9 d	Unknown
Female	46	Non-Hispanic White	Vermont	8	Negative	Fully ambulatory	Rituximab	Diabetes, hypertension, and morbid obesity	Yes–bilateral	30+ d	Antiviral, systemic glucocorticoids, other anti-inflammatory agents, oxygen therapy, IVIG, and convalescent plasma
Female	52	Black or African American	Kentucky	13	Positive	Fully ambulatory	Rituximab	Chronic lung disease and hypertension	Yes–bilateral	30+ d	Systemic glucocorticoids, azithromycin, other antibiotics, oxygen therapy, and IVIG

Abbreviations: COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy; IVIG = intravenous immunoglobulin; NMOSD = neuromyelitis optica spectrum disorders.

Table 3 Demographic and Clinical Characteristics of Patients With MOGAD Reported in the COVIMS Registry

Sex	Age	Race	US state at the time of COVID-19 onset	Disease duration	Ambulatory status	DMT at the time of COVID-19	Comorbidities	COVID-19 clinical severity outcome	Pneumonia	Length of hospital stay	COVID-19 treatments
Female	67	Black or African American	Unknown	15	Fully ambulatory	Mycophenolate	Cancer, chronic lung disease, and diabetes	Admitted to the ICU and/or ventilated	No	13–15 d	Hydroxychloroquine and systemic glucocorticoids
Male	54	Non-Hispanic White	Kansas	3	Fully ambulatory	Rituximab	Hypertension	Admitted to the ICU and/or ventilated	Yes–bilateral	7–9 d	Chloroquine, azithromycin, and oxygen therapy
Female	19	Non-Hispanic White	California	3	Fully ambulatory	Mycophenolate	No	Hospitalization only	Yes–bilateral	4–6 d	Hydroxychloroquine, azithromycin, and other antibiotics
Female	26	Non-Hispanic White	Unknown–United States	2	Fully ambulatory	Rituximab	Obesity	Not hospitalized	No	—	None
Female	58	Hispanic or Latino	Missouri	7	Fully ambulatory	None	No	Not hospitalized	No	—	Systemic glucocorticoids
Female	32	Other/unknown	California	3	Fully ambulatory	Rituximab	Morbid obesity	Not hospitalized	No	—	Azithromycin
Female	43	Non-Hispanic White	Kentucky	2	Walk with assistance	Azathioprine	Diabetes, hypertension, and morbid obesity	Not hospitalized	Yes–unilateral	—	Azithromycin
Female	20	Hispanic or Latino	Unknown–United States	8	Fully ambulatory	Fingolimod	Migraines	Not hospitalized	No	—	None
Female	62	Other/unknown	California	2	Fully ambulatory	Rituximab	None	Not hospitalized	No	—	Tylenol
Female	26	Non-Hispanic White	Rhode Island	2	Fully ambulatory	Rituximab	No	Not hospitalized	No	—	Unknown
Female	64	Other/unknown	Unknown–United States	0	Walk with assistance	Rituximab	Diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea	Not hospitalized	No	—	None
Female	25	Non-Hispanic White	Nebraska	15	Fully ambulatory	IVIg	None	Not hospitalized	No	—	Bamlanivimab
Male	69	Other/unknown	Canada	4	Fully ambulatory	None	Cancer and hypertension	Not hospitalized	No	—	None
Male	58	Non-Hispanic White	Ohio	2	Fully ambulatory	Rituximab	Hypertension and morbid obesity	Admitted to the ICU and/or ventilated	Yes–bilateral	1–3 d	Unknown monoclonal antibody infusion
Female	27	Non-Hispanic White	Canada	4	Fully ambulatory	Azathioprine	None	Not hospitalized	No	—	None
Male	27	Other/unknown	Canada	Unknown	Unknown	Unknown	None	Not hospitalized	No	—	Unknown

Continued

Table 3 Demographic and Clinical Characteristics of Patients With MOGAD Reported in the COViMS Registry (continued)

Sex	Age	Race	US state at the time of COVID-19 onset	Disease duration	Ambulatory status	DMT at the time of COVID-19	Comorbidities	COVID-19 clinical severity outcome	Pneumonia	Length of hospital stay	COVID-19 treatments
Female	38	Hispanic or Latino	New Jersey	15	Nonambulatory	Rituximab	None	Hospitalization only	No	Unknown	Unknown
Male	17	Non-Hispanic White	Unknown—United States	2	Fully ambulatory	None	Unknown	Not hospitalized	No	—	None
Male	60	Non-Hispanic White	Missouri	3	Fully ambulatory	None	None	Not hospitalized	No	—	None
Female	20	Other/unknown	Canada	11	Fully ambulatory	None	None	Not hospitalized	No	—	None

Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy; ICU = intensive care unit; IVIG = intravenous immunoglobulin; NMOSD = neuromyelitis optica spectrum disorders; MOGAD = myelin oligodendrocyte glycoprotein antibody disease.

Approximately two-thirds of patients with NMOSD in the COViMS Registry did not require hospitalization; however, 10.4% of the entire cohort died (8/77). This mortality rate is notable for being 4 times the rate than what was seen with patients with MS in COViMS and almost 6 times greater than that reported for the general population in the United States.^{1,4} However, a 95% CI ranging from 4.6% to 19.5% leaves some uncertainty as to the level of excess risk. A large percentage of the NMOSD cohort were Black and on rituximab, both of which are known risk factors for severe COVID-19 in other populations.^{1,2,5} The sole factor that identified statistically poorer COVID-19 outcome in NMOSD was the presence of a medical comorbidity, which resulted in 6-fold greater odds of worse COVID-19 outcomes. The most common medical comorbidities in this cohort were hypertension, diabetes, and morbid obesity, which have also been observed to increase risks of poor outcome from COVID-19 in the general population.

In the MS population within the COViMS Registry and in other registries/surveys, common risk factors for severe COVID-19 outcomes included older age, male sex, Black race, higher disability level, recent corticosteroid use, and use of B cell–depleting therapies.^{1,2,5} No demographic or DMT differences were observed in relation to NMOSD outcomes, although our statistical power to identify differences was limited. Overall, almost 60% of patients with NMOSD with COVID-19 in COViMS were treated with B cell–depleting therapies (46/77), and the proportion of NMOSD taking rituximab with fatal outcomes was nominally higher compared with those not taking rituximab (13.0% vs 6.5%). In addition, a large proportion of NMOSD were of Black race (29/77), and 4 of the 8 deaths were in NMOSD of Black race. Hence, with a larger sample size, rituximab and Black race could prove to be additional risk factors for severe COVID-19 in NMOSD. In fact, to achieve an 80% power to detect a difference in more severe outcomes between these groups, it would require over 200 patients per group. Thus, precautions to prevent exposure to SARS-CoV-2 in patients with NMOSD are recommended.^{6,7} Moreover, COVID-19 vaccination has been strongly encouraged by infectious disease experts and the Centers for Disease Control and Prevention, especially for those who are at high risk for more severe COVID-19 disease, and thus COVID-19 vaccination in NMOSD may be particularly important.^{6,7}

None of the 20 patients with MOGAD with COVID-19 in the COViMS Registry died, and only 5 required hospitalization. Patients with MOGAD in this cohort had similar comorbidities as those with NMOSD, and almost half were taking rituximab. Not identifying specific risks factors of poorer outcomes with COVID-19 in MOGAD is likely due to the small size of the cohort.

Altering B cell–depleting therapy dosage and/or frequency of administration during the COVID-19 pandemic has been

Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COVIMS

Factor	Total (N = 82)	MS (n = 74)	NMO (n = 8)	p Value
Sex				0.21 ^b
Male	35 (42.7)	34 (45.9)	1 (12.5)	
Female	46 (56.1)	39 (52.7)	7 (87.5)	
Nonbinary	1 (1.2)	1 (1.4)	0 (0.0)	
Age	60.9 (13.5)	62.1 (12.3)	50.1 (19.2)	0.016 ^e
Race				0.18 ^b
Non-Hispanic White	54 (65.9)	51 (68.9)	3 (37.5)	
Black or African American	20 (24.4)	16 (21.6)	4 (50.0)	
Hispanic or Latino	2 (2.4)	2 (2.7)	0 (0.0)	
Other/unknown	6 (7.3)	5 (6.8)	1 (12.5)	
Country at the time of COVID-19 onset^c				0.99 ^b
United States	77 (97.5)	70 (97.2)	7 (100.0)	
Canada	1 (1.3)	1 (1.4)	0 (0.0)	
Other	1 (1.3)	1 (1.4)	0 (0.0)	
Disease duration^c	19.3 (12.2)	20.6 (12.1)	9.3 (7.4)	0.012 ^e
Ambulatory status^c				0.075 ^b
Fully ambulatory	15 (20.5)	11 (16.9)	4 (50.0)	
Walk with assistance	20 (27.4)	18 (27.7)	2 (25.0)	
Nonambulatory	38 (52.1)	36 (55.4)	2 (25.0)	
Glucocorticoid during the last 2 months?				0.45 ^a
No	54 (76.1)	48 (75.0)	6 (85.7)	
Yes	6 (8.5)	5 (7.8)	1 (14.3)	
Unknown	11 (15.5)	11 (17.2)	0 (0.0)	
DMT at the time of COVID-19^c				0.002 ^b
Alemtuzumab	1 (1.3)	1 (1.5)	0 (0.0)	
Dimethyl fumarate	4 (5.3)	4 (5.9)	0 (0.0)	
Glatiramer acetate	2 (2.6)	2 (2.9)	0 (0.0)	
Interferon-beta	1 (1.3)	1 (1.5)	0 (0.0)	
Mycophenolate	1 (1.3)	1 (1.5)	0 (0.0)	
Natalizumab	3 (3.9)	3 (4.4)	0 (0.0)	
Ocrelizumab	19 (25.0)	19 (27.9)	0 (0.0)	
Rituximab	10 (13.2)	4 (5.9)	6 (75.0)	
Siponimod	2 (2.6)	2 (2.9)	0 (0.0)	
Teriflunomide	5 (6.6)	5 (7.4)	0 (0.0)	
Other	2 (2.6)	1 (1.5)	1 (12.5)	
None	26 (34.2)	25 (36.8)	1 (12.5)	
Rituximab use				<0.001 ^a
No	72 (87.8)	70 (94.6)	2 (25.0)	

Continued

Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COViMS (continued)

Factor	Total (N = 82)	MS (n = 74)	NMO (n = 8)	p Value
Yes	10 (12.2)	4 (5.4)	6 (75.0)	
Length of time on current DMT^c				0.99 ^b
<6 months	1 (2.1)	1 (2.4)	0 (0.0)	
6 or more months	46 (97.9)	40 (97.6)	6 (100.0)	
Have comorbidities?				0.99 ^b
No	6 (7.3)	6 (8.1)	0 (0.0)	
Yes	72 (87.8)	64 (86.5)	8 (100.0)	
Unknown	4 (4.9)	4 (5.4)	0 (0.0)	
Cancer	7 (8.5)	6 (8.1)	1 (12.5)	0.67 ^a
Cardiovascular disease	22 (26.8)	21 (28.4)	1 (12.5)	0.34 ^a
Cerebrovascular disease	1 (1.2)	1 (1.4)	0 (0.0)	0.99 ^b
Chronic kidney disease	7 (8.5)	6 (8.1)	1 (12.5)	0.67 ^a
Chronic liver disease	3 (3.7)	3 (4.1)	0 (0.0)	0.99 ^b
Chronic lung disease	7 (8.5)	5 (6.8)	2 (25.0)	0.079 ^a
Chronic neurologic disease	9 (11.0)	8 (10.8)	1 (12.5)	0.88 ^a
Diabetes	17 (20.7)	14 (18.9)	3 (37.5)	0.22 ^a
Hypertension	43 (52.4)	39 (52.7)	4 (50.0)	0.99 ^b
Immunodeficiency disease	4 (4.9)	4 (5.4)	0 (0.0)	0.99 ^b
Morbid obesity	19 (23.2)	15 (20.3)	4 (50.0)	0.058 ^a
Other	26 (31.7)	25 (33.8)	1 (12.5)	0.22 ^a
Pneumonia	27 (32.9)	22 (29.7)	5 (62.5)	0.061 ^a
Emergency department visited?				0.18 ^a
Yes	59 (72.0)	51 (68.9)	8 (100.0)	
No	8 (9.8)	8 (10.8)	0 (0.0)	
Unknown	15 (18.3)	15 (20.3)	0 (0.0)	
Hospitalized?				0.30 ^b
Yes	70 (85.4)	63 (85.1)	7 (87.5)	
No	9 (11.0)	9 (12.2)	0 (0.0)	
Unknown	3 (3.7)	2 (2.7)	1 (12.5)	
Admitted to the ICU?				0.27 ^b
Yes	51 (62.2)	45 (60.8)	6 (75.0)	
No	18 (22.0)	18 (24.3)	0 (0.0)	
Unknown	13 (15.9)	11 (14.9)	2 (25.0)	
Ventilation?				0.21 ^b
Yes	41 (50.0)	38 (51.4)	3 (37.5)	
No	22 (26.8)	21 (28.4)	1 (12.5)	
Unknown	19 (23.2)	15 (20.3)	4 (50.0)	

Continued

Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COViMS (continued)

Factor	Total (N = 82)	MS (n = 74)	NMO (n = 8)	p Value
Type of COVID-19 diagnosis				0.99 ^b
Laboratory positive	77 (93.9)	69 (93.2)	8 (100.0)	
Suspected COVID-19, not confirmed	5 (6.1)	5 (6.8)	0 (0.0)	

Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy. Values presented as mean ± SD, median (P25, P75), median (min, max) or N (column %).

^a Fisher exact test.

^b ANOVA.

^c Data not available for all patients. Missing values: country at the time of COVID-19 onset, disease duration = 10, ambulatory status = 9, glucocorticoid during the last 2 months, DMT at the time of COVID-19 = 6, and length of time on current DMT = 35.

^d Pearson χ^2 test.

^e Kruskal-Wallis test.

considered in patients with MS because of the mounting evidence that these agents increase the risk of infections, including COVID-19, in MS.^{1-3,8} Some studies have suggested that patients with MS can achieve similar suppression of new inflammatory disease activity with lower doses and/or extended intervals between doses of rituximab or ocrelizumab.⁹⁻¹² It is unclear whether these treatment approaches would be applicable to NMOSD but may be of interest especially because the main difference in clinical characteristics between patients with NMOSD and MS in COViMS was the use of rituximab. Of interest, 2 small case series in NMOSD have shown that it might be possible to prevent future clinical NMOSD relapses along with reducing the risk of infections by using lower doses of rituximab and/or with a decrease in frequency of rituximab infusions.^{13,14} Moreover, it may be reasonable in some patients (e.g., NMOSD with medical comorbidities and NMOSD with hypogammaglobulinemia) to consider tailoring their treatment regimen in hopes to minimize infectious risks.¹⁵

Last, in the COViMS Registry, 7 patients with NMOSD who were alive reported having neurologic symptoms in relation to COVID-19 including motor dysfunction (42.9%) and cognitive and sensory dysfunction (28.6%). Because of the nature of data collection in the COViMS Registry, it is unclear whether these symptoms were due to a provoked relapse, pseudorelapse, or neurologic complications from COVID-19 as has been seen in other patient populations.¹⁶ Neurologic symptoms were not reported in the patients with MOGAD in this registry.

Limitations of this study include the small sample size relative to more common diseases (e.g., MS). This study is not population-based, as has been a limitation in many COVID-19 studies. Reporting biases may be present; reporting is voluntary, and more severe outcomes might have been disproportionately captured. Additional risk factors for more severe COVID-19 outcomes might be uncovered with a larger sample size, with studies from areas of the world where NMOSD and MOGAD are

particularly prevalent, or when combining data from different registries.

Conclusions

Among the reported patients with NMOSD, a high mortality rate was observed, and the presence of comorbid conditions was associated with worse COVID-19 outcome. There were no deaths reported in the patients with MOGAD, an observation that was limited due to small sample size.

Overall, these results suggest that it is of utmost importance for people with NMOSD to be especially vigilant and avoid exposure and adopt measures to minimize the risk of infection by SARS-CoV-2. Data will continue to be collected via the COViMS Registry to help enhance our understanding of how infection by SARS-CoV-2 affects both NMOSD and MOGAD.

Acknowledgment

The COViMS Registry had robust participation from health care professionals across North America (<https://www.covims.org/reporter-acknowledgement>), and the authors thank all those who contributed information to this effort (see links.lww.com/NXI/A539).

Study Funding

Support for COViMS is provided by the National MS Society, the Consortium of Multiple Sclerosis Centers, and the MS Society of Canada. REDCap at Washington University in St. Louis is supported by Clinical and Translational Science Award (CTSA) Grant (UL1 TR000448) and Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant P30 CA091842.

Disclosure

S.D. Newsome has received consulting fees for scientific advisory boards from Biogen, Genentech, Bristol Myers Squibb, EMD Serono, Novartis, and Greenwich Biosciences; is an

advisor for Autobahn Therapeutics and BioIncept and a clinical adjudication committee member for a MedDay Pharmaceuticals clinical trial; and has received research funding (paid directly to institution) from Biogen, Novartis, Genentech, National MS Society, Department of Defense, and Patient-Centered Outcomes Institute. A.H. Cross received personal compensation from Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Greenwich Biosciences, Janssen Pharmaceuticals, and Novartis and has received research funding (paid directly to institution) from Genentech/Roche. R.J. Fox has received personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi, Teva, and TG Therapeutics. He has served on advisory committees for Actelion, Biogen, Immunic, and Novartis and received clinical trial contract and research grant funding from Biogen and Novartis. J. Halper, P. Kanellis, and B. Bebo report no disclosures. D. Li has received research funding from the Multiple Sclerosis Society of Canada. He is Emeritus Director of the UBC MS/MRI Research Group, which has been contracted to perform central analysis of MRI scans for therapeutic trials with Roche and Sanofi Genzyme. The UBC MS/MRI Research Group has also received grant support for investigator-initiated studies from Sanofi Genzyme, Novartis, and Roche. He has served on the PML-MS Steering Committee for Biogen and given lectures and supported by nonrestricted education grants from Academy of Health Care Learning, Biogen, Consortium of MS Centers, and Sanofi Genzyme. G. Cutter is a member of Data and Safety Monitoring Boards for Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Mapi Pharmaceuticals LTD, Merck, Merck/Pfizer, Opko Biologics, OncoImmune, Neurim, Novartis, Ophazyme, Sanofi-Aventis, Reata Pharmaceuticals, Teva pharmaceuticals, VielaBio Inc, Vivus, NHLBI (Protocol Review Committee), and NICHD (OPRU oversight committee). He is on consulting or advisory boards for Bidelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Klein-Buendel Inc, MedImmune, MedDay, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Roche, and TG Therapeutics. Dr. Cutter is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc., a private consulting company in Birmingham, AL. K. Rammohan receives grant funding from Roche/Genentech, Biogen, EMD Serono, MedDay Pharma, Novartis, TG Therapeutics, and the Department of Defense. He also participates in consulting or advisory groups for Roche/Genentech, Biogen, EMD Serono, and Novartis. A. Salter is a statistical editor for *Circulation: Cardiovascular Imaging*. Go to Neurology.org/NN for full disclosures.

Publication History

Received by *Neurology: Neuroimmunology & Neuroinflammation* April 1, 2021. Accepted in final form July 6, 2021.

Appendix Authors

Name	Location	Contribution
Scott D. Newsome, DO	Johns Hopkins University School of Medicine, Baltimore, MD	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data
Anne H. Cross, MD	Washington University in St. Louis School of Medicine, MO	Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data
Robert J. Fox, MD	Mellen Center for MS, Cleveland Clinic, OH	Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data
June Halper, MSN, APN-C	Consortium of MS Centers, Hackensack, NJ	Drafting/revision of the manuscript for content, including medical writing for content
Pamela Kanellis, PhD	MS Society of Canada, Toronto, Ontario, Canada	Drafting/revision of the manuscript for content, including medical writing for content
Bruce Bebo, PhD	National Multiple Sclerosis Society (USA), New York, NY	Drafting/revision of the manuscript for content, including medical writing for content
David Li, MD	University of British Columbia, Vancouver, British Columbia, Canada	Drafting/revision of the manuscript for content, including medical writing for content
Gary R. Cutter, PhD	The University of Alabama at Birmingham	Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data
Kottil W. Rammohan, MD	University of Miami School of Medicine, FL	Drafting/revision of the manuscript for content, including medical writing for content
Amber Salter, PhD	Washington University in St. Louis School of Medicine, MO	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data

References

1. Salter A, Fox RJ, Newsome SD, et al. SARS-CoV-2 infection in multiple sclerosis patients in North America: relationships of race, ethnicity, comorbidities and disease characteristics to COVID-19 disease course. *JAMA Neurol.* 2021;78(6):699-708.
2. Somani MP, De Rossi N, Schiavetti I, et al; Musc-19 Study Group. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. *Ann Neurol.* 2021;89(4):780-789.
3. Louapre C, Maillart E, Papeix C, et al. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. *Eur J Neurol.* 2020. doi: 10.1111/ene.14612. Epub ahead of print. PMID: 33103295.
4. Johns Hopkins University of Medicine Coronavirus Resource Center Mortality Analyses. coronavirus.jhu.edu/data/mortality (accessed 19 March 2021).
5. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. *Mult Scler Relat Disord.* 2020;43:102195.

6. CDC-How to protect yourself and others. [cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html) (accessed 19 March 2021).
7. COVID-19 vaccine guidance for people living with MS: [nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance](https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance) (accessed 19 March 2021).
8. Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. *JAMA Neurol.* 2020;77(2):184-191.
9. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. *Neurology.* 2016;87(20):2074-2081.
10. Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. *Mult Scler.* 2012;18(3):377-378.
11. Maarouf A, Rico A, Boutiere C, et al. Under the aegis of OFSEP. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? *Neurol Neuroimmunol Neuroinflamm.* 2020;7(5):e825.
12. Barun B, Gabelić T, Adamec I, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. *Mult Scler Relat Disord.* 2020;48:102704.
13. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. *Neurology.* 2013;81(8):710-713.
14. Lebrun C, Cohen M, Rosenthal-Allieri MA, et al. Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders. *Neurol Ther.* 2018;7(2):373-383.
15. Avouac A, Maarouf A, Stellmann JP, et al. Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated, *Bertrand Audoin Neurol Neuroimmunol Neuroinflamm.* 2021;8(3):e977.
16. Collantes MEV, Espiritu AI, Sy MCC, Anlanc VMM, Jamora RDG. Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis. *Can J Neurol Sci.* 2021;48(1):66-76.